In accordance with a study that reported trapping of palbociclib during the treatment phase within the melanoma cells [62], we suggest that this mechanism explains both the lack of p21 upregulation (Figure 3b) as well as the induction of SA-β-gal activity after treatment with Palbo-CM (Figure 6). This evidence concerns the gene CDKN1A and melanoma.